FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Overview of attention for article published in Clinical Cancer Research, March 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

So far, Altmetric has seen 19 X posts from 16 X users, with an upper bound of 51,656 followers.

RT @StephenVLiu: FDA approval summary of adjuvant atezolizumab for resected stage II-IIIA PDL1+ NSCLC (based on IMpower 010) available @CCR…

RT @StephenVLiu: FDA approval summary of adjuvant atezolizumab for resected stage II-IIIA PDL1+ NSCLC (based on IMpower 010) available @CCR…

RT @StephenVLiu: FDA approval summary of adjuvant atezolizumab for resected stage II-IIIA PDL1+ NSCLC (based on IMpower 010) available @CCR…

RT @lindamahj: FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for St…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 15 additional X posts.